oods-based, calorically dense, high-protein nutritional formula developed
for cancer patients undergoing chemotherapy or radiation treatments.
Resurgex(R) and Resurgex Plus(R) are specialized, anabolic nutritional
supplements rich in antioxidants that provide nutritional support
post-treatment. Millennium has also recently developed a Surgex(R) sports
nutrition formula, clinically proven to address the nutritional concerns of
both professional and amateur elite athletes. These athletes often
experience similar symptoms post-workout to those battling
immunocompromised conditions, such as fatigue, loss of lean muscle,
oxidative stress, and reduced immune function.
Statements in this news release regarding future financial and
operating results, future growth in R&D programs, potential applications of
the Company's technology, opportunities for the Company, and any other
statements about the future expectations, beliefs, goals, plans, or
prospects expressed constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Any
statements that are not statements of historical fact (including statements
containing the words "will," "believes," "plans," "anticipates," "expects,"
"estimates," and similar expressions) should also be considered to be
forward-looking statements. There are a number of important factors that
could cause actual results or events to differ materially from those
indicated by such forward- looking statements including: limited operating
history, need for future capital, risks inherent in the development and
commercialization of potential products, protection of the Company's
intellectual property, and economic conditions generally. Additional
information on potential factors that could affect results and other risks
and uncertainties are detailed from time to time in the Company's periodic
reports, including Forms 10-KSB, 10-QSB, 8-K, and other forms filed with
the Securities and Exchange Commis
'/>"/>
SOURCE Millennium Biotechnologies Inc. Copyright©2007 PR Newswire. All rights reserved | |
Page: 1 2 3 Related biology technology :1.
Thomas Weisel Partners 2007 Healthcare Conference To Webcast Millennium Presentation2.
Millennium Biotechnologies Group, Inc. (MBTG.OB) Announces Completion of $2,277,000 Equity Financing3.
Millennium Biotechnologies Group, Inc. (MBTG.OB) Announces Appointment of Mark C. Mirken as its President and Chief Operating Officer4.
Merrill Lynch Global Pharmaceutical, Biotech and Medtech Conference to Webcast Millennium Presentation5.
Life Sciences Leader Joins Millennium Board of Directors6.
Millennium to Webcast Third-Quarter 2007 Financial and Operational Results7.
Millennium Reports Outstanding Third-Quarter Results Driven by VELCADE(R) (Bortezomib) for Injection Sales8.
Millennium Research Group Offers New Marketrack Service that Tracks European Dental Implant Market9.
Millennium Biotechnologies, Inc. Launches SURGEX(TM) the First Scientifically Validated Sports Nutritional Product Created from the Medical Markets10.
Kiwa Bio-Tech Ships 2,700 Tons of Bio-feed in One Month11.
Alseres Pharmaceuticals, Inc. to Present at Windhovers Therapeutic Area Partnerships Conference